Abbott will acquire the Solvay Group, including the pharmaceutical and vaccine business, for $6.6 billion in cash, the company announced. Abbott expects Solvay Pharmaceuticals, based in Belgium, to bring in an additional $3 billion in annual sales, and extend the company's reach in emerging global markets.
Merck announced an exclusive agreement with CSL Biotherapies to market and distribute Afluria, a flu vaccine. The six-year deal extends through flu season of 2016. Financial terms of the deal were not disclosed. Merck also pays royalties to CSL for its intellectual property patent on Gardasil, Merck's HPV vaccine.
Johnson & Johnson announced a collaboration with Netherlands-based Crucell for the development of monoclonal antibodies and vaccines for the flu and other diseases. The partnership unites J&J subsidiary Ortho-McNeil-Janssen Pharmaceuticals with Crucell, in a $442 million deal that buys J&J an 18% ownership stake in Crucell. The partnership will immediately focus on the development and commercialization of a flu vaccine, according to a statement.